Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus LINCOMYCIN HCL.
CLEOCIN PHOSPHATE vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic